Business
Inogen Announces Appointment of Tom West to Board of Directors and Retirement of Board Member Kristen Miranda
GOLETA, Calif.--(BUSINESS WIRE)-- Inogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare
About this update from Inogen, Inc
[{"type":"text","content":" GOLETA, Calif.--(BUSINESS WIRE)--\nInogen, Inc. (Nasdaq: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, today announced the appointment of Tom West to Inogen’s Board of Directors, effective April 1, 2023. The company also announced that Kristen Miranda, who has served as a director since March 2021, will retire as a member of the Board of Directors, effective March 31, 2023.\n\n“We are pleased to welcome Tom West to the Inogen Board. Tom brings additional general management and operational experience to the Inogen Board with his history of leadership and business success in medical technology and life sciences healthcare spaces,” said Elizabeth Mora, Chairperson of the Board. “Under the leadership of Nabil Shabshab, Inogen’s President and CEO, we have made significant progress in rebuilding Inogen into a MedTech company that is capable of delivering durable growth as we successfully execute on our strategic initiatives, advance our prescriber growth strategy and drive productivity and efficiency of our commercial operations. The addition of Tom West will further elevate the partnership between the Board and the executive team to advance Inogen’s transformation into a global respiratory care leader.”\n\n“On behalf of the Board of Directors, I would also like to thank Kristen Miranda for her commitment and many valuable contributions to the Board,” said Ms. Mora. \"She has brought a lot of experience and thought partnership around the healthcare space and channel dynamics, specifically around the aspects of consumer health.”\n\nTom West serves as President and Chief Executive Officer and is an executive Director of the Board of Nalu Medical, Inc., a privately held medical technology company focused on neurostimulation to treat chronic intractable pain. He joined Nalu in August 2022. Before joining Nalu, Mr. West served from 2019 to 2022 as President, Chief Executive Officer and Director at Intersect ENT, Inc., a publicly traded medical device and drug delivery company in the sinus surgery space. Intersect ENT was acquired by Medtronic in May of 2022 doubling its enterprise value in less than three years despite the COVID pandemic. Prior to Intersect, Mr. West served as Worldwide President, Diagnostic Solutions at Hologic from 2015 to 2019. Mr. West began his healthcar...